Student Publications

Student Scholarship

Fall 2021

Rhabdomyolysis and COVID-19
Brett T. Swanson
Gettysburg College

Follow this and additional works at: https://cupola.gettysburg.edu/student_scholarship
Part of the Epidemiology Commons, and the Musculoskeletal Diseases Commons

Share feedback about the accessibility of this item.
Recommended Citation
Swanson, Brett T., "Rhabdomyolysis and COVID-19" (2021). Student Publications. 954.
https://cupola.gettysburg.edu/student_scholarship/954

This open access student research paper is brought to you by The Cupola: Scholarship at Gettysburg College. It has
been accepted for inclusion by an authorized administrator of The Cupola. For more information, please contact
cupola@gettysburg.edu.

Rhabdomyolysis and COVID-19
Abstract
This paper seeks to summarize recent research findings concerning the link between rhabdomyolysis and
COVID-19. While most commonly known as a respiratory disease, COVID-19 has strong direct effects on
the kidneys which presents a serious challenge to treatment and care of patients. New research also
suggests that COVID-19 directly damages skeletal muscle tissue as well, and rhabdomyolysis induced as
a result of viral attack or secondary factors can also place major strain on the kidneys. Both COVID-19
and rhabdomyolysis can lead to acute kidney injury on their own, and their combined effects can present
severe clinical complications. This body of research must be developed further in order to inform patient
care techniques and adapt to further mutations in the SARS-CoV-2 virus as the pandemic continues.

Keywords
Rhabdomyolysis, COVID-19, Acute Kidney Injury, Skeletal Muscle, Pandemic

Disciplines
Epidemiology | Medicine and Health Sciences | Musculoskeletal Diseases

Comments
Written for HS 311: Neuromuscular Physiology

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

This student research paper is available at The Cupola: Scholarship at Gettysburg College:
https://cupola.gettysburg.edu/student_scholarship/954

1

Rhabdomyolysis and COVID-19
Brett Swanson
Health Sciences Department, Gettysburg University
HS 311: Neuromuscular Physiology
Dr. Daniel Drury
1 December 2021

2

Abstract
This paper seeks to summarize recent research findings concerning the link between
rhabdomyolysis and COVID-19. While most commonly known as a respiratory disease, COVID19 has strong direct effects on the kidneys which presents a serious challenge to treatment and
care of patients. New research also suggests that COVID-19 directly damages skeletal muscle
tissue as well, and rhabdomyolysis induced as a result of viral attack or secondary factors can
also place major strain on the kidneys. Both COVID-19 and rhabdomyolysis can lead to acute
kidney injury on their own, and their combined effects can present severe clinical complications.
This body of research must be developed further in order to inform patient care techniques and
adapt to further mutations in the SARS-CoV-2 virus as the pandemic continues.
Introduction
SARS-CoV-2 was first reported and studied in China, and has since grown into a global,
multi-year pandemic. The virus’s severity is generally understood to be related to its effects on
the respiratory system, but there is an increasing amount of research demonstrating additional
effects, symptoms, and complications related it. One such complication is rhabdomyolysis,
which is more often associated with the breakdown of striated muscle tissue rather than lung
tissues. A number of proposed mechanisms for this have recently started to be developed, which
should be synthesized in order to better inform further research into this developing field.
Rhabdomyolysis is COVID-19 patients is concerning because of the dual severity of both
diseases, either of which having the capability to kill the patient. Therefore, the
interconnectedness of these diseases will be discussed in this paper as a comparative analysis,
with the goal of highlighting similarities and cascading mechanisms. Typical pathophysiology of
rhabdomyolysis has to do with the breakdown of skeletal muscle and the impact it has on kidney
function, whereas pathophysiology of SARS-CoV-2 has also been found to both directly and
indirectly damage muscle and kidney tissue.
Rhabdomyolysis
Rhabdomyolysis is the accumulation of broken-down striated muscle in the kidneys. This
buildup stresses the kidneys’ elimination ability, and can lead to further systemic damage and
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shutdown. The reasons for muscle breakdown are numerous, and can be broadly categorized as
traumatic or non-traumatic (Cabral et al., 2020).
Etiology
Trauma and crushing injuries such as natural disasters, vehicle collisions, and even highvoltage electrical injury are common causes of rhabdomyolysis (Cabral et al., 2020) (Brumback
et al., 1995). Prolonged compression of blood vessels or immobilization during a traumatic
event, coma, surgery, tourniquet application etc. can result in muscle ischemia and hypoxia.
Rhabdomyolysis occurs after this compression is relieved, and necrotic debris enters the
bloodstream (Khan, 2009).
Rhabdomyolysis also occurs as a result of exertional injury, infections, hyperthermia,
drugs, and toxins. Exertion through exercise or other means such as seizures can lead to
rhabdomyolysis by combining mechanical and thermal damage to muscle tissue with ATP
depletion. Drugs, toxins, and electrolyte imbalances can create conditions such as hypoxia,
lowered ATP production ability, increased sarcolemma permeability, and so on. All of these
conditions can be exacerbated by genetic disorders, many of such first presenting in childhood
(Cabral et al., 2020).
Pathophysiology
From these myriad causes of rhabdomyolysis is a common pathway of events, beginning
with destruction of the sarcolemma and depletion of ATP which leads to increased intracellular
calcium. From cell membrane destruction, the calcium flows directly past the broken cell wall.
From ATP depletion, the lack of ATP to operate the Na+/K+ channel means intracellular sodium
is exchanged for calcium. This causes persistent muscle contraction and energy depletion that
destroys membrane proteins. This then leads to cell lysis, and cell contents make their way into
the bloodstream, primarily potassium, myoglobin, and creatine kinase (CK) (Bosch et al., 2009).
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In the extracellular space and bloodstream, myoglobin is normally bound to plasma
globulins. However, this binding capacity can quickly become overwhelmed, and just 100g of
muscle tissue breakdown can lead to precipitation of myoglobin in the glomerular filtrate. When
this happens, the renal tubules can become occluded and severe damage can occur. Renal
damage also occurs due to the direct cytotoxic effect by myoglobin on renal cells, renal
vasoconstriction, urate precipitation, and direct oxidative damage to renal tissue (Cervellin et al.,
2017).
Clinical Manifestation and Diagnosis
A rhabdomyolysis patient will have varying presentation of symptoms depending on the
severity of the muscle damage. The traditional symptoms of the disease are muscle pain,
weakness, and dark-coloured urine. However, the most common complaints from patients are
swelling, stiffness, cramping, and muscle pain. Frequently, the muscle groups involved are
proximal ones such as thighs, calves, or the lower back. On the systemic level, symptoms such as
fever, abdominal pain, nausea and vomiting, and general malaise are commonly described
(Cabral et al., 2020).
Diagnosis of rhabdomyolysis relies on laboratory tests, with the key indicator being
serum CK level. CK is the most sensitive indicator of skeletal muscle injury, corresponding
strongly with the degree of damage or development of compartment syndrome (Huerta-Alardín
et al., 2005). However, it does not correlate very much with acute kidney injury (AKI)
development (Fernandez et al., 2005). Multiple measurements of CK should be made to watch
for increasing or non-declining levels, which would suggest ongoing muscle injury or possibly
renal failure (Zimmerman & Shen, 2013).
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Another indicator is myoglobin level. Development of rhabdomyolysis means myoglobin
content is high enough in urine to change its colour to a red-brown shade. Myoglobin is a useful
early indicator of rhabdomyolysis because it appears before CK elevation, but has a short halflife and thus can be missed if disease presentation is delayed (Huerta-Alardín et al., 2005)
(Zimmerman & Shen, 2013).
Urinalysis tests are frequently used to detect myoglobinuria. However, the test has low
sensitivity and specificity, and so is not considered essential (Zimmerman & Shen, 2013).
Abnormalities in electrolyte levels should be monitored along with renal function, as
hypokalemia and hypophosphatemia, and especially hyperkalemia need to be identified.
Hyperkalemia can lead to cardiac arrhythmia or cardiac arrest and must be addressed. Because of
this, hypokalemia should not be corrected unless the patient is symptomatic to minimize risk of
calcium phosphate accumulation in the injured muscle. Additionally, around 20-30% of patients
will develop hyperkalemia during recovery (Cabral et al., 2020).
Rhabdomyolysis-induced Acute Kidney Injury
Acute kidney injury (AKI) can occur in around 10% of patients who have
rhabdomyolysis (Zutt et al., 2014). Glomerular filtration rate with rhabdomyolysis is likely
impacted through renal vasoconstriction, tubule obstruction, or direct and ischemic tubule injury.
Mitigation of AKI relies first on treatment of the cause of muscle injury, whether it is
temperature control, infection treatment, or so on. Appropriate hydration early on and continued
is imperative for AKI treatment, with patients often needing up to 10 liters of fluid a day. Once
AKI is developed, there is no specific therapy, and dialysis may be needed for correcting
metabolic abnormalities (Cabral et al., 2020).
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Because of the myriad factors and complications of rhabdomyolysis as well as the
associated kidney damage, prognosis of the disease varies widely. Despite this, available
evidence indicates excellent prognosis if it is treated early and aggressively. AKI arising from
severe injury has a very wide range of mortality rates, from 7-80%. In most cases however, AKI
is able to be completely reversed and recovered from in a matter of months (Cabral et al., 2020).
COVID-19
Pathophysiology
Coronavirus disease 2019 (COVID-19) is a virus that targets the respiratory tract when
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) particles enter. The disease
presents with fever, dry cough, dyspnea, and diarrhea, and the severity of it can range from
asymptomatic infection to multi-organ failure (Ertuğlu et al., 2020). Respiratory failure is the
main effect of severe cases. However, evidence points to the kidney as the second most affected
organ (Li et al., 2020). SARS-CoV-2 particles have also been shown to spread to other body
tissues such as the central nervous system, intestine, and cardiac muscle (Ali & Kunugi, 2021).
Morbidity of the disease is also higher in patients with preexisting cardiac conditions, indicating
that cellular and tissue function even outside the respiratory tract may be directly impaired
(Wang et al., 2020) (Tavazzi et al., 2020).
The SARS-Cov-2 virus functions by binding via spike proteins to cells’ angiotensinconverter enzyme receptor 2 (ACE-2 receptors), and subsequently sending viral RNA through
this attachment. ACE-2 is highly expressed in particular cell types such as type II alveolar
epithelial cells (de Oliveira et al., 2021).
The function of ACE-2 is to turn angiotensin II (AGII) into angiotensin 1-7 (AG1-7). The
properties of AG1-7 are vasodilatory, anti-inflammatory, and natriuretic. AGII itself is a
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powerful vasoconstriction-inducing hormone, and is synthesized from angiotensin I (AGI) by
angiotensin-converting enzyme (ACE). It is also a pro-inflammatory marker. When SARS-CoV2 uses the ACE-2 receptor to enter a cell, it also downregulates ACE-2 expression, leading to
increased levels of AGII due to lack of a negative feedback mechanism turning it into AG1-7.
AGII then promotes neutrophil infiltration into organs, production of cytokines, and vascular
permeability, with all of these factors leading to tissue and organ damage (Chong & Saha, 2021).
Skeletal Muscle Damage
Muscle soreness (myalgia) is the third most common symptom of the disease after fever
and cough. This soreness and subsequent loss of skeletal muscle is still not fully understood in
terms of mechanism, but it seems to be the intersection of many factors. Old age, along with
metabolic and inflammatory disorders exacerbated by old age increase the chance of muscle
damage. Older populations are also the primary patients of COVID-19. Patients with these
complications typically have some degree of muscle wasting (sarcopenia). Sarcopenic muscle
produces myokines and adipokines, which lead to inflammation and oxidative stress on the
tissues. Under these conditions, proinflammatory cytokines are produced, which in great number
lead to direct organ and tissue damage, including skeletal muscle (Ali & Kunugi, 2021).
Skeletal muscle also displays ACE-2 receptors (Saud et al., 2021) (Paliwal et al., 2020).
Recent evidence points to the ability of the SARS-CoV-2 virus to directly enter skeletal muscle
cells via these receptors by using viral spike proteins to attach to them and link the viral envelope
with the cell membrane for insertion of viral genetic material. This is notable in that it would
suggest that this virus is the first virus capable of directly infecting skeletal muscle fibres
(Dalakas, 2020).
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Kidney Damage
The kidney is vulnerable to attack from SARS-CoV-2 due to the number of kidney cell
types that display ACE-2 receptors. These cells include mesangial cells, the Bowman’s capsule
parietal epithelium, collecting ducts, and podocytes (de Oliveira et al., 2021). While the full
impact of SARS-CoV-2 on the kidney and kidney failure is still under investigation, recent
studies have found renal dysfunction to be increasingly linked with the disease. Both albuminuria
and proteinuria have been observed in hospitalized patients, and both inflammation and edema
have been detected in patients’ kidney tissues (Ahmadian et al., 2020). The targeting of the
kidney by the virus is reported to be a frequent occurrence (Naicker et al., 2020).
The exact mechanisms of renal involvement are also unclear, but there is a proposed
pathway that combines various factors. These factors include direct renal damage from viral
action and replication; homeostatic imbalance of the renin-angiotensin-aldosterone system
(RAAS); deregulation of the compliment system cascade; and a “cytokine storm” of
inflammatory factors and their consequences (de Oliveira et al., 2021).
It is likely that the primary factor leading to AKI in patients with severe COVID-19 is
acute renal tubule injury due to hemodynamic instability (de Oliveira et al., 2021). However, in
milder cases, where patients have relatively mild respiratory symptoms, no septic shock, and no
acute respiratory distress syndrome (ARDS), direct kidney disfunction such as collapsing
glomerulopathy has been reported. This suggests that the virus directly or indirectly infects the
renal tissue itself (Sharma et al., 2020).
COVID-19 Related Rhabdomyolysis
Recent studies have shown that rhabdomyolysis may be related to COVID-19 as a latedeveloping complication (Jin & Tong, 2020) (Khosla et al., 2020) or even as a presenting
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problem (Valente-Acosta et al., 2020) (Chedid et al., 2020) (Alrubaye & Choudhury, 2020). In
influenza infection, rhabdomyolysis has been found to most likely occur as a direct result of viral
invasion of myocytes. The mechanism behind COVID-19 related rhabdomyolysis is still unclear,
but is thought to be secondary to viral invasion or direct muscle damage induced by
inflammatory mediators such as cytokines (Ahmadian et al., 2020) (Bach et al., 2021).
Viral factors are not the only contributor to rhabdomyolysis, so it cannot be ruled out that
skeletal muscle damage is due to some other mechanism than viral attack. There is existing
literature from before the COVID-19 pandemic describing how the drugs hydroxychloroquine
and oseltamivir can lead to the development of rhabdomyolysis. These drugs are used in the
treatment of COVID-19, and so should be considered a possible cause of rhabdomyolysis (Borku
Uysal et al., 2020).
AKI as an observed clinical event in COVID-19 is more common than rhabdomyolysis
diagnoses, with existing reports showing 4-7% of patients developing AKI, which is similar to
the development shown in the original SARS outbreak. Preliminary reports of rhabdomyolysis
were anecdotal only, and remain a small minority of cases (Solís et al., 2020). AKI occurrence
does not necessarily indicate the occurrence of rhabdomyolysis. Conversely, some patients who
had not developed AKI have had markers of rhabdomyolysis such as pigment casts and
inflammation, which proposes the possibility that extensive sub-clinical renal damage had
occurred (Ahmadian et al., 2020). Although rare, rhabdomyolysis in COVID-19 patients is
probably underdiagnosed, and should be considered in patients with muscle weakness, dark
urine, unexplained hyperkalemia, metabolic acidosis, or disproportionate myalgia (Solís et al.,
2020).
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Treatment
There is currently no specific treatment for COVID-19 related AKI or rhabdomyolysis.
Treatment must be done on the specific symptoms, with consideration to any change in state,
especially blood and urine markers. A potential therapeutic approach is the restoration of the
impaired RAAS homeostasis in order to reverse the disfunction of that renal mechanism directly
caused by viral activity. No matter what treatments are chosen, care needs to be taken to ensure
that positive effects outweigh the negative, and the treatments are personalized to each patient
(Smarz-Widelska et al., 2021).
Conclusions
The existing body of research on the mechanisms of SARS-CoV-2 still needs to be
developed further, especially in regard to damage and impairment of body functions outside the
lungs, which are understood to be the primary site of the disease. The pandemic has highlighted
the clinical concerns of such a widespread outbreak, such as the lack of resources to manage
patients in and out of hospitals, new treatments, and new vaccines. There is an existing case
study of a patient developing rhabdomyolysis after receiving the Pfizer vaccine. Such a rare sideeffect does not call into question any theory of vaccine usage, but does indicate that
unprecedented situations will arise. Various social factors such as vaccine inequality or
skepticism must also be addressed in order to eventually end the pandemic. On a per-patient
basis, factors can arise rapidly and be treated promptly and with an informed outlook, and this
still holds true for a population and international scope.
Just as information gained from previous viral disease outbreaks such as the original
SARS, MERS, and influenza has informed current analyses of SARS-CoV-2, these current
analyses can inform future perspectives on viral mechanisms. The pandemic is not likely to go
away any time soon, and with the various different mutations of the virus being detected, a body
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of research that evolves with the changing conditions of the pandemic is much more desirable
than a stagnant one.
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